Skip to main content

Table 6 Group comparison (mean ± SD) in secondary outcome measures between patients on lovastatin vs. placebo

From: Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

OutcomeLovastatin+PILIPlacebo+PILI
BaselinePostBaselinePost
Receptive vocab growth score134.75 ± 31.76136.92 ± 33.87137.44 ± 22.71136.44 ± 19.79
Expressive vocab growth score143.5 ± 22.12142.67 ± 24.53141.44 ± 14.45142.75 ± 12.91
Expressive grammar raw score10.18 ± 11.3611 ± 12.668.33 ± 6.419.93 ± 7.59
Receptive grammar raw score22.18 ± 18.9122.17 ± 20.2321.4 ± 9.2620.2 ± 11.98
Parent strategy: recasts3.28 ± 2.6729.67 ± 13.345.48 ± 5.0724.79 ± 12.57
Parent strategy: WH-questions9.56 ± 9.0640.36 ± 20.6913.19 ± 8.5733.25 ± 17.73
Parent strategy: fill-in-the-blank prompts2.06 ± 2.7419.56 ± 11.963.21 ± 6.9616.5 ± 14.24
ABC-C – total score44.5 ± 28.4340.5 ± 31.8355.5 ± 30.1844.06 ± 25.36
RBS-R – total score27.75 ± 17.4328.67 ± 23.932.19 ± 18.8426.19 ± 20.14
Clinical Global Impression (CGI)4.581 ± 0.672.422 ± 0.674.501 ± 0.632.382 ± 0.72
VAS: spoken language impairment4.06 ± 2.435.66 ± 1.991.94 ± 1.414.18 ± 1.53
VAS: social impairment3.73 ± 1.745.18 ± 1.702.55 ± 1.363.99 ± 2.06
  1. 1CGI-severity ratings collected at baseline visit
  2. 2CGI-improvement ratings collected at post-treatment visit